{"id":"factor-viii-fviii","safety":{"commonSideEffects":[{"rate":null,"effect":"Inhibitor development (anti-Factor VIII antibodies)"},{"rate":null,"effect":"Thrombotic events"},{"rate":null,"effect":"Hypersensitivity reactions"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Factor VIII is a critical cofactor in the intrinsic coagulation pathway that works with von Willebrand factor and other factors to activate Factor X, ultimately leading to thrombin generation and fibrin clot formation. In hemophilia A, Factor VIII is either absent or non-functional, leading to impaired clotting. Replacement therapy restores the ability to form stable blood clots and prevent or treat bleeding episodes.","oneSentence":"Factor VIII is a clotting factor that replaces deficient or dysfunctional coagulation factor VIII to restore blood clotting ability in hemophilia A patients.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:12:14.157Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hemophilia A (congenital Factor VIII deficiency)"},{"name":"Acquired hemophilia A"}]},"trialDetails":[{"nctId":"NCT07285460","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-12-18","conditions":"Hemophilia","enrollment":85},{"nctId":"NCT06940830","phase":"PHASE4","title":"Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa","status":"RECRUITING","sponsor":"Swedish Orphan Biovitrum","startDate":"2025-05-21","conditions":"Hemophilia A","enrollment":250},{"nctId":"NCT04293523","phase":"","title":"A 48-Month Study to Evaluate Long-Term Effectiveness of Elocta on Joint Health","status":"ACTIVE_NOT_RECRUITING","sponsor":"Swedish Orphan Biovitrum","startDate":"2020-03-30","conditions":"Hemophilia A","enrollment":427},{"nctId":"NCT06224907","phase":"PHASE3","title":"Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia A","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioMarin Pharmaceutical","startDate":"2023-12-25","conditions":"Hemophilia A","enrollment":6},{"nctId":"NCT03588299","phase":"PHASE1, PHASE2","title":"Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a \"Shuttle\"","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2018-11-07","conditions":"Hemophilia A","enrollment":11},{"nctId":"NCT07088458","phase":"","title":"An Observational Study to Learn More About How Well Damoctocog Alfa Pegol Works in Previously Treated Children With Hemophilia A","status":"NOT_YET_RECRUITING","sponsor":"Bayer","startDate":"2026-04-30","conditions":"Hemophilia A","enrollment":40},{"nctId":"NCT06998524","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-06-27","conditions":"Von Willebrand Disease, Type 3","enrollment":75},{"nctId":"NCT06883240","phase":"","title":"An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-04-29","conditions":"Von Willebrand Disease, Type 3","enrollment":40},{"nctId":"NCT06111638","phase":"PHASE2, PHASE3","title":"Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs","status":"RECRUITING","sponsor":"Shanghai Xinzhi BioMed Co., Ltd.","startDate":"2024-01-03","conditions":"Hemophilia A","enrollment":55},{"nctId":"NCT07416526","phase":"PHASE3","title":"A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A","status":"NOT_YET_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2026-05-09","conditions":"Hemophilia A","enrollment":126},{"nctId":"NCT07226206","phase":"PHASE1, PHASE2","title":"A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2026-03-31","conditions":"Hemophilia A","enrollment":5},{"nctId":"NCT07032792","phase":"PHASE2","title":"Factor VIII Inhibitor Bypass Activity (FEIBA) Versus Fresh Frozen Plasma As First Line Therapy For Bleeding After Cardiac Surgery","status":"RECRUITING","sponsor":"Northwell Health","startDate":"2025-11-03","conditions":"Cardiac Disease, Surgery, Bleeding","enrollment":140},{"nctId":"NCT07416604","phase":"PHASE3","title":"A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A","status":"NOT_YET_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2026-04-30","conditions":"Hemophilia A","enrollment":360},{"nctId":"NCT03932201","phase":"","title":"Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2019-10-21","conditions":"Hemophilia A","enrollment":371},{"nctId":"NCT04461639","phase":"","title":"Study to Learn More About the Safety of Drug Jivi Over a Long Period of Time in Previously Treated Patients With Hemophilia A (Bleeding Disorder Resulting From a Lack of FVIII) Who Are Receiving Jivi Regularly at Their Treating Doctors to Prevent Bleeding","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2021-05-14","conditions":"Hemophilia A","enrollment":62},{"nctId":"NCT06349473","phase":"PHASE1","title":"A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)","status":"RECRUITING","sponsor":"Equilibra Bioscience LLC","startDate":"2024-05-10","conditions":"Healthy Participants, Hemophilia A, Hemophilia B","enrollment":31},{"nctId":"NCT05987449","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-09-21","conditions":"Hemophilia A","enrollment":60},{"nctId":"NCT07446010","phase":"","title":"Post Approval Observational Study to Learn More About How Safe Octocog Alfa is and How Well it Works in Patients With Severe Hemophilia A in India","status":"NOT_YET_RECRUITING","sponsor":"Bayer","startDate":"2026-03-10","conditions":"Severe Hemophilia A","enrollment":33},{"nctId":"NCT07437404","phase":"PHASE3","title":"Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients.","status":"RECRUITING","sponsor":"Sinocelltech Ltd.","startDate":"2024-04-26","conditions":"Haemophilia A","enrollment":36},{"nctId":"NCT07439055","phase":"PHASE2, PHASE3","title":"Real-World Joint Outcomes After Selective Transition to Low-Dose Emicizumab in Pediatric Hemophilia A","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chulalongkorn University","startDate":"2025-06-01","conditions":"Hemophilia A Patient","enrollment":18},{"nctId":"NCT05568719","phase":"PHASE3","title":"Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively","status":"RECRUITING","sponsor":"Pfizer","startDate":"2022-12-28","conditions":"Hemophilia A, Hemophilia B","enrollment":173},{"nctId":"NCT07425327","phase":"","title":"Validity and Reliability of the Two-minute Step Test in Hemophilia","status":"NOT_YET_RECRUITING","sponsor":"Hasan Kalyoncu University","startDate":"2026-02-25","conditions":"Hemophilia, Step, Reliability and Validity","enrollment":35},{"nctId":"NCT07420348","phase":"","title":"Incidence of Ultrasonographically Detected Articular Damage in Initially Healthy Joints of Patients With Hemophilia A Receiving Prophylactic Treatment With Emicizumab","status":"NOT_YET_RECRUITING","sponsor":"Investigación en Hemofilia y Fisioterapia","startDate":"2026-02-27","conditions":"Hemophilia","enrollment":70},{"nctId":"NCT04953884","phase":"PHASE3","title":"Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease (VWD) Patients <6 Years of Age","status":"COMPLETED","sponsor":"Octapharma","startDate":"2021-09-22","conditions":"Von Willebrand Disease","enrollment":12},{"nctId":"NCT04158934","phase":"","title":"A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baxalta now part of Shire","startDate":"2020-07-09","conditions":"Hemophilia A","enrollment":207},{"nctId":"NCT04563520","phase":"PHASE3","title":"SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis","status":"RECRUITING","sponsor":"Emory University","startDate":"2026-03","conditions":"Hemophilia A","enrollment":5},{"nctId":"NCT06579144","phase":"PHASE1","title":"Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A","status":"RECRUITING","sponsor":"Swedish Orphan Biovitrum","startDate":"2025-02-24","conditions":"Hemophilia A","enrollment":24},{"nctId":"NCT07414511","phase":"","title":"Hemophilia A Research Program","status":"RECRUITING","sponsor":"University of Washington","startDate":"2024-07-31","conditions":"Hemophilia A, Hemophilia A, Severe, Factor VIII (FVIII)","enrollment":500},{"nctId":"NCT05932914","phase":"","title":"Liver Biopsy Following Gene Therapy For Hemophilia","status":"NOT_YET_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2026-03","conditions":"Hemophilia A, Hemophilia B","enrollment":8},{"nctId":"NCT06574984","phase":"","title":"Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2024-11-10","conditions":"Congenital Bleeding Disorder, Haemophilia A","enrollment":900},{"nctId":"NCT07410130","phase":"","title":"Clinical Spectrum and Management of Von Willebrand Disease Among Children in Assiut Governorate","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-03","conditions":"Von Willebrand Disease (VWD), Inherited Bleeding Disorders in Children, Pediatric Hemostatic Disorders","enrollment":25},{"nctId":"NCT07406139","phase":"PHASE4","title":"PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A）","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Hemophilia, Inhibitors","enrollment":30},{"nctId":"NCT03384277","phase":"PHASE4","title":"Trial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2017-12-29","conditions":"Acquired Hemophilia A","enrollment":66},{"nctId":"NCT07400848","phase":"","title":"Clinical Laboratory Evaluation, Assessment of Symptoms and Recovery in Patients With Post-COVID-19-Vaccination Syndrome","status":"RECRUITING","sponsor":"University of Bern","startDate":"2026-02-15","conditions":"Post-Acute COVID-19 Vaccination Syndrome, Postviral Fatigue","enrollment":200},{"nctId":"NCT05145127","phase":"PHASE3","title":"Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors","status":"RECRUITING","sponsor":"Pfizer","startDate":"2021-11-17","conditions":"Hemophilia A, Hemophilia B","enrollment":245},{"nctId":"NCT05662319","phase":"PHASE3","title":"A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2023-02-01","conditions":"Hemophilia","enrollment":91},{"nctId":"NCT04431726","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-02-04","conditions":"Severe Hemophilia A","enrollment":55},{"nctId":"NCT06716814","phase":"PHASE3","title":"Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa","status":"RECRUITING","sponsor":"Swedish Orphan Biovitrum","startDate":"2025-03-06","conditions":"Severe Haemophilia A","enrollment":104},{"nctId":"NCT05181618","phase":"PHASE4","title":"A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-06-20","conditions":"Severe Hemophilia A, Moderate Hemophilia A","enrollment":136},{"nctId":"NCT04158648","phase":"PHASE3","title":"A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-02-10","conditions":"Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor, Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor, Hemophilia A","enrollment":73},{"nctId":"NCT05147662","phase":"PHASE3","title":"A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood","status":"COMPLETED","sponsor":"Bayer","startDate":"2022-03-23","conditions":"Treatment of Bleeding, Prophylaxis of Bleeding, Hemophilia A","enrollment":36},{"nctId":"NCT06530030","phase":"","title":"Goal Attainment and Physical Activity in People With Hemophilia A","status":"TERMINATED","sponsor":"Sanofi","startDate":"2024-11-26","conditions":"Hemophilia A","enrollment":3},{"nctId":"NCT06222697","phase":"","title":"A Study to Learn More About the Safety of Damoctocog-alfa-pegol When Used in Routine Medical Care in Korean Participants With Hemophilia A","status":"RECRUITING","sponsor":"Bayer","startDate":"2024-01-24","conditions":"Hemophilia A, Prophylaxis of Bleeding, Treatment of Bleeding","enrollment":20},{"nctId":"NCT05022459","phase":"","title":"Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis","status":"RECRUITING","sponsor":"Wayne State University","startDate":"2023-08-16","conditions":"Hemophilia A","enrollment":72},{"nctId":"NCT05936580","phase":"PHASE4","title":"Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery","status":"RECRUITING","sponsor":"Octapharma","startDate":"2026-04","conditions":"Hemophilia A","enrollment":28},{"nctId":"NCT05768386","phase":"","title":"A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)","status":"ENROLLING_BY_INVITATION","sponsor":"BioMarin Pharmaceutical","startDate":"2023-01-01","conditions":"Hemophilia A","enrollment":172},{"nctId":"NCT04647227","phase":"PHASE4","title":"SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors","status":"RECRUITING","sponsor":"American Thrombosis and Hemostasis Network","startDate":"2021-06-28","conditions":"Hemophilia A With Inhibitor, Hemophilia B With Inhibitor","enrollment":55},{"nctId":"NCT07129343","phase":"PHASE3","title":"A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-10-13","conditions":"Von Willebrand Disease (VWD)","enrollment":20},{"nctId":"NCT06738485","phase":"PHASE3","title":"Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products","status":"RECRUITING","sponsor":"CSL Behring","startDate":"2025-01-09","conditions":"Congenital Hemophilia A","enrollment":60},{"nctId":"NCT07314983","phase":"","title":"Long-term Anticoagulation in a Patient With Severe Hemophilia A","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2025-09-22","conditions":"Hemophilia A","enrollment":1},{"nctId":"NCT04204408","phase":"PHASE2","title":"A Research Study Investigating Mim8 in People With Haemophilia A","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-01-10","conditions":"Healthy Volunteers, Haemophilia A With or Without Inhibitors","enrollment":275},{"nctId":"NCT06752850","phase":"PHASE4","title":"A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Swedish Orphan Biovitrum","startDate":"2024-12-19","conditions":"Haemophilia A (Moderate or Severe), Hemophilia, Classic, Haemophilia","enrollment":37},{"nctId":"NCT04146376","phase":"","title":"Von Willebrand Factor in Pregnancy (VIP) Study","status":"RECRUITING","sponsor":"University of Washington","startDate":"2019-10-12","conditions":"Von Willebrand Diseases","enrollment":110},{"nctId":"NCT03754790","phase":"PHASE3","title":"Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genzyme, a Sanofi Company","startDate":"2019-01-09","conditions":"Hemophilia","enrollment":281},{"nctId":"NCT06833983","phase":"PHASE3","title":"To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A","status":"RECRUITING","sponsor":"Gritgen Therapeutics Co., Ltd.","startDate":"2025-03-31","conditions":"Hemophilia A","enrollment":50},{"nctId":"NCT07265843","phase":"PHASE4","title":"Fibrinogen in Liver Transplant","status":"NOT_YET_RECRUITING","sponsor":"Trauma Hemostatis and Oxygenation Research (THOR) Network","startDate":"2026-01-01","conditions":"Liver Transplant Surgery","enrollment":60},{"nctId":"NCT06922045","phase":"PHASE3","title":"Phase III Clinical Trial of STSP-0601 for Injection in Hemophilia Patients","status":"RECRUITING","sponsor":"Jiangsu BioJeTay Biotechnology Co., Ltd.","startDate":"2025-03-26","conditions":"Hemophilia","enrollment":32},{"nctId":"NCT06941870","phase":"PHASE4","title":"Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-09-23","conditions":"Factor VIII Deficiency","enrollment":35},{"nctId":"NCT03818763","phase":"PHASE1","title":"Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2020-04-29","conditions":"Hemophilia A","enrollment":5},{"nctId":"NCT05036278","phase":"PHASE4","title":"Prophylaxis Regimen for Hemophilia A Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2022-07-28","conditions":"Hemophilia A, Prophylaxis of Bleeding","enrollment":21},{"nctId":"NCT03695978","phase":"","title":"Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients","status":"RECRUITING","sponsor":"Octapharma","startDate":"2018-02-13","conditions":"Haemophilia A","enrollment":200},{"nctId":"NCT03587116","phase":"PHASE3","title":"A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-07-26","conditions":"Hemophilia B, Hemophilia A","enrollment":212},{"nctId":"NCT05345197","phase":"PHASE2","title":"Emicizumab in Patients With Acquired Hemophilia A","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2022-08-31","conditions":"Acquired Hemophilia A","enrollment":51},{"nctId":"NCT05935358","phase":"PHASE4","title":"Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study","status":"RECRUITING","sponsor":"Octapharma","startDate":"2023-11-28","conditions":"Severe Hemophilia A","enrollment":28},{"nctId":"NCT02941783","phase":"","title":"Drug Use Investigation of Kovaltry in Hemophilia A Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-11-30","conditions":"Hemophilia A","enrollment":230},{"nctId":"NCT07218185","phase":"","title":"Comparative Effectiveness of INTERCEPT Fibrinogen Complex (IFC) and Cryoprecipitate-AHF (Cryo-AHF) for Treatment of Trauma Associated Hemorrhage","status":"NOT_YET_RECRUITING","sponsor":"Cerus Corporation","startDate":"2026-05","conditions":"Hypofibrinogenemia, Hemorrhage","enrollment":320},{"nctId":"NCT05582993","phase":"PHASE3","title":"A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-11-06","conditions":"Von Willebrand Disease (VWD)","enrollment":24},{"nctId":"NCT05817812","phase":"PHASE3","title":"A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa","status":"ACTIVE_NOT_RECRUITING","sponsor":"Swedish Orphan Biovitrum","startDate":"2023-07-31","conditions":"Hemophilia A, Severe","enrollment":93},{"nctId":"NCT04323098","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A","status":"COMPLETED","sponsor":"BioMarin Pharmaceutical","startDate":"2020-12-08","conditions":"Hemophilia A","enrollment":22},{"nctId":"NCT06684314","phase":"","title":"A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in Taiwan","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-11-11","conditions":"Hemophilia A","enrollment":100},{"nctId":"NCT05911763","phase":"","title":"A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2023-06-30","conditions":"Hemophilia A","enrollment":200},{"nctId":"NCT07200609","phase":"NA","title":"The Effects of Virtual Reality-Based Gamified Rehabilitation in Children With Hemophilia","status":"NOT_YET_RECRUITING","sponsor":"Hacettepe University","startDate":"2025-11","conditions":"Hemophilia A Without Inhibitor","enrollment":20},{"nctId":"NCT03061201","phase":"PHASE2","title":"A Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 (PF-07055480) in Subjects With Severe Hemophilia A","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-06-21","conditions":"Hemophilia A","enrollment":13},{"nctId":"NCT06145373","phase":"PHASE4","title":"A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-03-01","conditions":"Hemophilia A","enrollment":20},{"nctId":"NCT07190118","phase":"","title":"Effects of Emicizumab Treatment in Patients With Hemophilia A","status":"NOT_YET_RECRUITING","sponsor":"Hasan Kalyoncu University","startDate":"2025-09-30","conditions":"Hemophilia A, Musculoskeletal Assessment, Musculoskeletal Abnormalities","enrollment":20},{"nctId":"NCT07187661","phase":"NA","title":"Intra-Articular Bevacizumab for Preventing Recurrent Hemarthrosis in Hemophilia With Chronic Synovitis","status":"RECRUITING","sponsor":"Khyber Medical University Peshawar","startDate":"2025-09-09","conditions":"Hemophilia, Chronic Synovitis","enrollment":25},{"nctId":"NCT05042440","phase":"PHASE1","title":"Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia A","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-08-11","conditions":"Hemophilia A","enrollment":13},{"nctId":"NCT06312475","phase":"PHASE3","title":"Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou Alphamab Co., Ltd.","startDate":"2024-01-09","conditions":"Hemophilia A With Inhibitor, Hemophilia B With Inhibitor","enrollment":53},{"nctId":"NCT04161495","phase":"PHASE3","title":"A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A","status":"COMPLETED","sponsor":"Bioverativ, a Sanofi company","startDate":"2019-11-19","conditions":"Factor VIII Deficiency","enrollment":159},{"nctId":"NCT06569108","phase":"PHASE3","title":"Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou Alphamab Co., Ltd.","startDate":"2024-04-01","conditions":"Hemophilia A Without Inhibitor, Hemophilia B Without Inhibitor","enrollment":125},{"nctId":"NCT03315455","phase":"PHASE3","title":"Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-04-26","conditions":"Hemophilia A","enrollment":85},{"nctId":"NCT04759131","phase":"PHASE3","title":"Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A","status":"COMPLETED","sponsor":"Bioverativ, a Sanofi company","startDate":"2021-02-19","conditions":"Hemophilia A","enrollment":74},{"nctId":"NCT03370172","phase":"PHASE1, PHASE2","title":"A Study of BAX 888 in Male Adults With Severe Hemophilia A","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2018-02-27","conditions":"Hemophilia A","enrollment":4},{"nctId":"NCT05248594","phase":"","title":"Real World Use of Emicizumab in Infants and Children Ages 0-3 Years With Hemophilia A","status":"COMPLETED","sponsor":"Montefiore Medical Center","startDate":"2024-08-01","conditions":"Hemophilia A","enrollment":71},{"nctId":"NCT04023019","phase":"","title":"Treatment of Hemophilia A Patients With FVIII Inhibitors","status":"RECRUITING","sponsor":"Emory University","startDate":"2020-03-17","conditions":"Hemophilia A","enrollment":120},{"nctId":"NCT03879135","phase":"PHASE3","title":"A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2019-04-01","conditions":"Von Willebrand Disease (VWD)","enrollment":38},{"nctId":"NCT05643560","phase":"","title":"An Observational Study Called JOIHA to Learn More About How Well the Treatment With Jivi Works to Prevent Problems With Joints in Adults With Hemophilia A.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2022-12-29","conditions":"Hemophilia A, Prophylaxis of Bleeding","enrollment":33},{"nctId":"NCT06634836","phase":"","title":"Patient Interview Study to Explore the Impact of Gene Therapy in Hemophilia A & B","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2025-03-17","conditions":"Hemophilia A, Hemophilia B","enrollment":""},{"nctId":"NCT03520712","phase":"PHASE1, PHASE2","title":"Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5","status":"TERMINATED","sponsor":"BioMarin Pharmaceutical","startDate":"2018-04-24","conditions":"Hemophilia A, Gene Therapy, Clotting Disorders","enrollment":3},{"nctId":"NCT06339567","phase":"NA","title":"Evaluation of the Venous Thrombotic Biological Profile of Different PCOS Phenotypes: French Cross-sectional Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondation Hôpital Saint-Joseph","startDate":"2024-02-08","conditions":"Polycystic Ovary Syndrome","enrollment":352},{"nctId":"NCT04370054","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2020-08-18","conditions":"Hemophilia A","enrollment":77},{"nctId":"NCT06273865","phase":"","title":"Version Testing of EnzySystem Version A for Hemophilia A","status":"SUSPENDED","sponsor":"Radboud University Medical Center","startDate":"2024-05-29","conditions":"Hemophilia A","enrollment":40},{"nctId":"NCT05611801","phase":"PHASE3","title":"A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B","status":"RECRUITING","sponsor":"Pfizer","startDate":"2022-12-09","conditions":"Hemophilia A, Hemophilia B","enrollment":100},{"nctId":"NCT06703606","phase":"PHASE1","title":"A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-05-13","conditions":"Severe Hemophilia A","enrollment":15},{"nctId":"NCT06550882","phase":"","title":"A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South Korea","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-07-22","conditions":"Acquired Hemophilia A","enrollment":9},{"nctId":"NCT07116993","phase":"NA","title":"Effects of Ultrasound and Infrared on Joint Pain and Movement in Hemophilia A Patients.","status":"COMPLETED","sponsor":"Danyal Ahmad","startDate":"2024-03-01","conditions":"Hemophilia A","enrollment":30},{"nctId":"NCT06764927","phase":"PHASE4","title":"Fibrinogen in Liver Transplant Subjects","status":"NOT_YET_RECRUITING","sponsor":"Ezeldeen Abuelkasem","startDate":"2025-10-31","conditions":"Liver Transplant Surgery","enrollment":30},{"nctId":"NCT03974113","phase":"PHASE3","title":"Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genzyme, a Sanofi Company","startDate":"2020-01-28","conditions":"Hemophilia","enrollment":32},{"nctId":"NCT07099313","phase":"","title":"Association of Prophylactic Treatment With Treatment Burden and Psychosocial Variables in Patients With Hemophilia","status":"RECRUITING","sponsor":"Investigación en Hemofilia y Fisioterapia","startDate":"2025-07-31","conditions":"Hemophilia","enrollment":114},{"nctId":"NCT05849740","phase":"PHASE4","title":"An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia A","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-05-22","conditions":"Acquired Hemophilia","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3310,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Afstyla","Kovaltry"],"phase":"phase_3","status":"active","brandName":"Factor VIII (FVIII)","genericName":"Factor VIII (FVIII)","companyName":"Hoffmann-La Roche","companyId":"hoffmann-la-roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Factor VIII is a clotting factor that replaces deficient or dysfunctional coagulation factor VIII to restore blood clotting ability in hemophilia A patients. Used for Hemophilia A (congenital Factor VIII deficiency), Acquired hemophilia A.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}